GlassScriptPhysician profile
Brooke A Caufield
NPI 1063593184
$2,125.57
in general payments reported to CMS, 2019-2025
28 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $61.44 · 2021: $205 · 2022: $145 · 2023: $348 · 2024: $456 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $396.42 | 2019-2025 | |
| Abbvie INC. | $192.36 | 2019-2025 | Skyrizi |
| Novartis Pharmaceuticals Corporation | $156.73 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $150.12 | 2023-2024 | Sotyktu |
| Ucb, INC. | $141.36 | 2024 | Bimzelx |
| Almirall LLC | $138.92 | 2019-2025 | Klisyri |
| Pfizer INC. | $137.50 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $115.77 | 2021-2025 | Ilumya |
| Leo Pharma INC. | $109.43 | 2022-2025 | Adbry |
| Incyte Corporation | $78.44 | 2021-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $76.53 | 2019-2022 | |
| Lilly USA, LLC | $74.57 | 2019-2023 | Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $39.72 | 2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $36.21 | 2019-2024 | Cabtreo |
| Dermavant Sciences, INC. | $30.24 | 2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $26.08 | 2025 | Vtama |
| Takeda Pharmaceuticals U.S.A., INC. | $23.57 | 2019 | |
| Janssen Biotech, INC. | $22.24 | 2020 | |
| Journey Medical Corporation | $21.89 | 2025 | |
| Galderma Laboratories, L.P. | $20.47 | 2024 | |
| Genentech USA, INC. | $19.15 | 2019 | |
| Aclaris Therapeutics, INC. | $18.81 | 2019 | |
| Dusa Pharmaceuticals, INC. | $18.06 | 2019 | |
| Verrica Pharmaceuticals INC. | $17.82 | 2024 | Ycanth |
| Allergan, INC. | $17.24 | 2022 | |
| Biofrontera INC. | $17.07 | 2019-2021 | |
| Botanix Sb INC | $16.37 | 2025 | Sofdra |
| Merck Sharp & Dohme LLC | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Caufield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.